Pfizer's pill, with the brand name Paxlovid, could secure U.S. regulatory approval by the end of the year.
-Pfizer Inc's experimental antiviral pill to treat COVID-19 was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday, offering what could be a promising new weapon in the fight against the pandemic.
Shares in Pfizer, which also makes one of the mostly widely used COVID-19 vaccines, were up 9% to $47.82, while Merck's were down 9.3% to $82.09. Shares of vaccine makers took a hit, with Moderna Inc, Pfizer's German partner BioNTech SE and Novavax all down 13-21%. "Vaccines are going to be the most effective and reliable tool that we have in this pandemic," said Dr. Grace Lee, professor of pediatrics at Stanford University School of Medicine. "These oral medications are going to augment our ability to really reduce the risk of severe disease, hospitalization and death, which is huge, but it won't prevent infection.
The company said it expects to manufacture 180,000 treatment courses by the end of this year and at least 50 million courses by the end of next year, including 21 million in the first half of 2022. Among those given Pfizer's drug within three days of symptom onset, the pill lowered the chances of hospitalization or death for adults at risk of developing severe COVID-19 by 89% compared to patients who received a placebo. Among these patients, 0.8% were hospitalized and none died by 28 days after treatment, compared to a 7% hospitalization rate and seven deaths in the placebo group.
An FDA panel of outside experts is scheduled to meet Nov. 30 to discuss Merck's pill, which was approved by British regulators https://www.reuters.com/business/healthcare-pharmaceuticals/britain-approves-mercks-oral-covid-19-pill-2021-11-04 in a world first on Thursday. Pfizer said it did not know if Paxlovid would be reviewed at that meeting.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Pfizer's COVID-19 pill, Paxlovid, cuts hospitalizations, deaths by 89%'An extraordinary effect': Pfizer says its COVID-19 pill reduced the risk of hospitalization and death by 89% in high-risk patients
Leer más »
Pfizer: Antiviral pill cuts risk of severe Covid by 89% – latest updatesPfizer says antiviral pill cuts rate of hospitalisation, death by 89 percent. Other Covid19 updates: 🇩🇪 Germany sees second straight case record 🇰🇷 South Korea buys 30M doses of Pfizer's vaccine for 2022 🇯🇵 Japan eases border rules More here:
Leer más »
Covid: Pfizer says antiviral pill 89% effective in high risk casesThe company stopped clinical trials early because initial results for the drug were so positive.
Leer más »
Pfizer Says Its COVID-19 Pill Is Highly EffectiveAn experimental antiviral pill appears to work very well at keeping people who are at high risk of severe COVID-19 from being admitted to the hospital and dying, according to the drug’s maker, Pfizer.
Leer más »
Pfizer says its experimental pill reduces risk of hospitalization, death from Covid-19Drugmaker Pfizer said Friday its experimental pill designed to fight coronavirus reduced the risk of hospitalization and death for high-risk patients taking part in a trial of the drug.
Leer más »